Contained in this deck is ___________________
Content: Comfort, Mobility, Inflammation drugs, Anti-infective, Antineoplastic agents
Concepts: Comfort, Mobility, Inflammation
Chapters 24 Neurologic and Neuromuscular Agents
Chapters 25, 26 Anti-inflammatories, Analgesics
Chapters 29, 30, 31 Antibacterial and Anti-infective Agents
Chapters 32, 33, 34 Additional Anti-infective Agents
Chapters 37, 38, 39 Antineoplastic Agents
a. Cardiovascular system and postural muscles
b. Central nervous system (CNS), memory, and cognition
c. Gastrointestinal system (GI) and lower extremity muscles
d. Respiratory system and facial muscles
ANS: D
d. Respiratory system and facial muscles
Myasthenia gravis causes fatigue and muscular weakness of the respiratory system, facial muscles, and extremities. It does not directly affect the cardiovascular system, CNS, or GI systems.
a. increase binding of acetylcholine (ACh) molecules to ACh receptors.
b. increase the amount of ACh available at neuromuscular junction sites.
c. reduce the number of acetylcholine receptor sites.
d. reduce the autoimmune destruction of ACh receptor sites.
ANS: D
d. reduce the autoimmune destruction of ACh receptor sites.
Myasthenia gravis is an autoimmune disorder involving an antibody response against a subunit of the ACh receptor site. Since the thymus is involved in systemic immunity, it is thought that removing the thymus can inhibit this process. It does not increase binding of ACh molecules to receptors or increase the amount of ACh or reduce the number of ACh receptor sites.
a. Excessive salivation
b. Muscle spasms
c. Muscle weakness
d. Respiratory paralysis
ANS: C
c. Muscle weakness
Neostigmine must be given on time to prevent myasthenic crisis, which is characterized by generalized, severe muscle weakness. The other symptoms are characteristic of cholinergic crisis, caused by too much medication.
a. Assess the patient for signs of ptosis.
b. Notify the provider to discuss an order for intravenous immune globulin (IVIG).
c. Obtain an order for atropine sulfate.
d. Request an order for an extra dose of pyridostigmine.
ANS: C
c. Obtain an order for atropine sulfate.
Severe muscle weakness, excess salivation, fasciculations of facial muscles, and pupil constriction are the major signs of cholinergic crisis, caused by excess pyridostigmine. The antidote is atropine, so the nurse should obtain an order to give this. Ptosis is sign of myasthenic crisis. IVIG is given to treat symptoms of MG and not used for cholinergic crisis. Giving extra pyridostigmine would increase the symptoms.
a. Contact the provider to request an order for atropine sulfate.
b. Contact the provider to request an order for edrophonium chloride (Tensilon).
c. Report signs of cholinergic crisis to the provider.
d. Report signs of myasthenic crisis to the provider.
ANS: B
b. Contact the provider to request an order for edrophonium chloride (Tensilon).
Overdosing and underdoing of AChE inhibitors have similar symptoms: muscle weakness, dyspnea, and dysphagia. Edrophonium may be used to diagnose MG or to distinguish between myasthenic crisis and cholinergic crisis since it is a very short-acting AChE inhibitor. When given, if the symptoms are alleviated, the cause is myasthenic crisis; if symptoms worsen, it is cholinergic crisis. Since patients can have similar symptoms, the nurse cannot report one or the other to the provider without more information.
a. Atropine sulfate
b. Edrophonium bromide (Tensilon)
c. Intravenous immune globulin (IVIG)
d. Pyridostigmine HCl (Mestinon)
ANS: D
d. Pyridostigmine HCl (Mestinon)
In this case, edrophonium is used to diagnose myasthenia gravis. Since symptoms improved with the AChE inhibitor, the patient will benefit from a longer-acting AChE inhibitor such as pyridostigmine. Atropine is given for AChE inhibitor overdose. Edrophonium is very short-acting, so it will not be used for treatment. IVIG is used when other AChE inhibitors fail.
a. Cerebral palsy
b. Multiple sclerosis
c. Muscle spasms
d. Myasthenia gravis
ANS: D
d. Myasthenia gravis
Improvement of symptoms after administration of edrophonium is diagnostic for myasthenia gravis.
a. Administer atropine sulfate to prevent cholinergic crisis.
b. Monitor the patient closely for respiratory distress.
c. Suggest that the nurse dilute the medication with colloidal fluids.
d. Tell the nurse to slow the rate of infusion of the pyridostigmine.
ANS: D
d. Tell the nurse to slow the rate of infusion of the pyridostigmine.
When given, IV pyridostigmine should be administered undiluted at a rate of 0.5 mg/min and should not be added to IV fluids. It is not necessary to administer atropine, since the patient is not symptomatic of cholinergic crisis.
a. Cerebral palsy (CP)
b. Multiple sclerosis (MS)
c. Myasthenia gravis (MG)
d. Parkinson’s disease (PD)
ANS: B
b. Multiple sclerosis (MS)
Diplopia and weakness of the extremities are two symptoms of MS. CP is characterized by muscle spasticity. MG involves generalized weakness, especially of facial muscles and respiratory muscles. PD manifests as tremors and difficulty moving and walking.
a. Cerebrospinal fluid (CSF) immunoglobulin G and magnetic resonance imaging (MRI)
b. CSF proteins and an angiography
c. Serum albumin and a computed tomography (CT) scan
d. Serum anti-acetylcholine antibodies and x-rays
ANS: A
a. Cerebrospinal fluid (CSF) immunoglobulin G and magnetic resonance imaging (MRI)
Laboratory tests that may suggest MS include CSF IgG and MRI.
a. Carisoprodol (Soma)
b. Chlorzoxazone (Parafon forte DSC)
c. Cyclobenzaprine (Flexeril)
d. Methocarbamol (Robaxin)
ANS: C
c. Cyclobenzaprine (Flexeril)
Cyclobenzaprine is a muscle relaxant that does not cause drug dependence. The other muscle relaxants can cause drug dependence.
a. “I may experience dizziness and drowsiness when I take this drug.”
b. “I should not consume alcohol while taking this medication.”
c. “I should take this medication with food to decrease stomach upset.”
d. “I will take this medication for three weeks and then stop taking it.”
ANS: D
d. “I will take this medication for three weeks and then stop taking it.”
This medication should not be stopped abruptly. Patients may experience dizziness and drowsiness. Alcohol will compound the central nervous system sedative effects. To decrease gastrointestinal upset, the nurse should counsel the patient to take it with food.
a. changing to cyclobenzaprine (Flexeril).
b. continuing the carisoprodol for 1 more week.
c. discontinuing the carisoprodol now.
d. ordering a taper of the carisoprodol.
ANS: D
d. ordering a taper of the carisoprodol.
Muscle relaxants can cause drug dependence and should not be withdrawn abruptly. The nurse should discuss a drug taper.
a. “MS is characterized by degeneration of neurons and nerves in the brain and spinal cord.”
b. “MS is characterized by lesions or plaques on myelin sheaths of nerves.”
c. “MS is characterized by neuritic plaques and neurofibrillary tangles in the CNS.”
d. “MS is characterized by weak muscles and decreased nerve impulses caused by decreased ACh.”
ANS: B
b. “MS is characterized by lesions or plaques on myelin sheaths of nerves.”
MS is characterized by lesions on myelin sheaths of nerves.
a. Adrenocorticotropic hormone (ACTH)
b. Cyclophosphamide (Cytoxan)
c. Glatiramer acetate (Copaxone)
d. Interferon-B (IFN-B)
ANS: A
a. Adrenocorticotropic hormone (ACTH)
ACTH is given to treat an acute attack of MS. Glatiramer acetate and interferon are used for remission-exacerbation states. Cyclophosphamide is given for chronic, progressive symptoms.
a. Adrenocorticotropic hormone (ACTH)
b. Cyclophosphamide (Cytoxan)
c. Cyclobenzaprine (Flexeril)
d. Interferon-B (IFN-B)
ANS: D
d. Interferon-B (IFN-B)
This patient is showing signs of remission and exacerbation of MS symptoms. Interferon is used to treat this phase. ACTH is used for acute attacks. Cyclophosphamide is used for chronic, progressive symptoms. Cyclobenzaprine is a centrally acting muscle relaxant that is used for muscle spasms to decrease pain and increase range of motion.
a. Acute attack phase
b. Chronic, progressive phase
c. End-stage phase
d. Remission-exacerbation phase
ANS: B
b. Chronic, progressive phase
Cyclophosphamide is used to treat MS patients who are in the chronic, progressive phase.
a. Baclofen (Lioresal)
b. Chlorzoxazone (Parafon forte)
c. Pancuronium bromide (Pavulon)
d. Methocarbamol (Robaxin)
ANS: C
c. Pancuronium bromide (Pavulon)
Pancuronium bromide is used as a depolarizing muscle relaxant during anesthesia.
a. Administer the next dose of methocarbamol since this is a harmless side effect.
b. Contact the provider to discuss changing to cyclobenzaprine (Flexeril).
c. Obtain an order for a complete blood count to evaluate blood loss.
d. Request an order for liver function tests since this indicates hepatotoxicity.
ANS: A
a. Administer the next dose of methocarbamol since this is a harmless side effect.
Urine may turn green, brown, or black in patients taking methocarbamol, and this is a harmless side effect. There is no need to change medications or order lab tests.
a. Bradycardia
b. Rash
c. Vomiting
d. Fever
e. Drooling
f. Weakness
ANS: A, C, E, F
a. Bradycardia
c. Vomiting
e. Drooling
f. Weakness
Bradycardia, drooling, and weakness can all occur with cholinergic crisis.
a. converts arachidonic acid into a chemical mediator for inflammation.
b. directly causes vasodilation and increased capillary permeability.
c. irritates the gastric mucosa to cause gastrointestinal upset.
d. releases prostaglandins, which cause inflammation and pain in tissues.
ANS: A
a. converts arachidonic acid into a chemical mediator for inflammation
COX-2 is an enzyme that converts arachidonic acid into prostaglandins and their products, and this synthesis causes pain and inflammation. They do not act directly to cause inflammation. COX-1 irritates the gastric mucosa. COX-2 synthesizes but does not release prostaglandins.
a. exert direct actions to cause relaxation of smooth muscle.
b. inhibit cyclooxygenase that is necessary for prostaglandin synthesis.
c. interfere with neuronal pathways associated with prostaglandin action.
d. suppress prostaglandin activity by blocking tissue receptor sites.
ANS: B
b. inhibit cyclooxygenase that is necessary for prostaglandin synthesis.
NSAIDs act by inhibiting COX-1 and COX-2 to help block prostaglandin synthesis. They do not have direct action on tissues, nor do they interfere with chemical receptor sites or neuronal pathways.
a. Counsel the patient to discuss a prescription NSAID with the provider.
b. Recommend adding aspirin to increase the antiinflammatory effect.
c. Suggest asking the provider about a short course of corticosteroids.
d. Tell the patient to increase the dose to 800 mg every 4 hours.
ANS: A
a. Counsel the patient to discuss a prescription NSAID with the provider.
The patient should discuss another NSAID with the provider if tolerance has developed to the over-the-counter NSAID. Patients should not take aspirin with NSAIDs because of the increased risk of bleeding and gastrointestinal upset. Steroids are not the drugs of choice for arthritis because of their side effects and are not used unless inflammation is severe. A prescription NSAID would be used prior to starting corticosteroids. Increasing the dose will increase side effects but may not increase desired effects. The maximum dose per day is 2400 mg, which would most likely be exceeded when increasing the dose to 800 mg every 4 hours.